Low sexual desire can be difficult to discuss, especially when it impacts emotional health, relationships, or self-esteem. Bremelanotide is one prescription therapy that has offered an additional option for treating certain types of hypoactive sexual desire disorder (HSDD) in women who are experiencing ongoing problems with sexual desire. This category of treatment relates to a peptide that is commonly known as PT-141 or Nexxana Bremelanotide.

Bremelanotide is not like medications that mainly work on blood flow or hormone levels. Instead, it works on melanocortin receptors in signalling in the brain. This difference makes it an interesting option for eligible premenopausal women, but there are important limitations to its effectiveness, safety profile and approved uses.

What Is Nexxana Bremelanotide?

Nexxana Bremelanotide is a bremelanotide-based prescription product associated with Nexxana Desire. Nexxana Desire is a medication intended to treat women’s low sexual desire. Bremelanotide is a synthetic peptide acting on melanocortin receptors. It is also known as PT-141 and is the active ingredient in the FDA-approved prescription drug Vyleesi.

There is an important distinction between the active ingredient and the commercial treatment. In 2019, the FDA approved Vyleesi for acquired generalised hypoactive sexual desire disorder in premenopausal women distressed by low sexual desire. Such approval does not mean that each product or formulation sold under another brand is automatically separately approved by the FDA. Consumers should check the actual medication, formulation, prescribing arrangements and dispensing pharmacy.

Nexxana Bremelanotide is therefore best viewed as a prescription bremelanotide treatment rather than an independently established drug category. This is not a general libido booster, not an over-the-counter product, and not a proven treatment for every cause of diminished sexual interest.

How Does Nexxana (Bremelanotide) Work?

Bremelanotide works by activating melanocortin receptors within the CNS. They are involved in diverse biological functions including appetite regulation , pigmentation and sexual response . In women with certain types of HSDD, PT-141 may improve sexual desire by affecting signalling pathways in the brain.

This mechanism is different from treatments that mainly increase blood flow to genital tissues. Bremelanotide does not act like a typical hormone replacement therapy or a direct vasodilator, but rather targets the neural pathways that are responsible for sexual drive and libido. This mechanism has been studied by researchers, as sexual interest is composed of many interrelated elements such as brain activity, emotional responses and physical health.

The exact mechanism of its clinical effects is not completely understood. Therefore, Nexxana Bremelanotide should not be expected to work the same for everyone. It also doesn’t automatically fix relationship problems, psychological distress or medication-related changes in libido, or underlying medical conditions.

Nexxana Bremelanotide Advantages

The main potential benefit of bremelanotide is improvement in sexual desire in appropriately selected premenopausal women with acquired, generalised HSDD. In clinical trials, desire scores were statistically significantly improved and distress associated with low sexual desire was statistically significantly reduced compared to placebo. This is the clinical evidence for the drug, though improvement doesn't necessarily mean a full return to the previous level of sexual interest.

It may also be useful on an as-needed basis. Conversely, the FDA-approved bremelanotide injection is used as needed rather than as a daily medication. This method may be useful for patients who desire treatment at the time of expected sexual activity. But you do have to plan ahead, since you have to have the injection at least 45 minutes before, and the duration of effectiveness hasn’t been fully determined.

Nexxana Bremelanotide may also appeal to patients looking for a treatment that works through neurological pathways, rather than traditional hormone replacement. This distinction can be important in discussions with your health-care provider about treatment options. However, bremelanotide should not replace evaluation of hormonal, psychological, relational or medical causes of decreased sexual desire.

Research on more than 1,200 women in two pivotal phase 3 trials showed significant improvement in sexual desire and related distress. But the results of trials should be seen in perspective. Not everyone responds, side effects can get in the way of treatment, and the medication is not indicated for sexual enhancement or treating low desire in all populations.

Nexxana Bremelanotide Side Effects and Dangers

Nausea is the most common side effect of bremelanotide. Other reactions may occur such as flushing, headache, vomiting, irritation at the injection site. In clinical trials, about 40% of patients taking the approved medication reported nausea, and some discontinued treatment due to the severity of the side effect. Nausea can be a major limitation, and while usually less of a problem with subsequent doses, may persist.

Another safety consideration is its effect on cardiovascular measurements. Bremelanotide administration may lead to transient increases in blood pressure and decreases in heart rate. Not to be used by persons with uncontrolled hypertension or a history of heart disease. And for those at high risk of cardiovascular events, careful medical assessment is needed before treatment is even considered.

Focal hyperpigmentation (localised darkening of the skin) has also been described. Changes can include the face, gums and breasts and may not go away completely when treatment stops. The risk is greater the more often it is given and may be greater in people with darker skin. Other precautions may involve interactions with some oral medications, especially those drugs whose absorption may be delayed by delayed gastric emptying. Pregnancy and special considerations regarding opioid-based drugs may also be factors. Full medication and medical history should be reviewed before use.

Nexxana Bremelanotide Who Should Use?

The indication for bremelanotide is a specific FDA-approved indication for premenopausal women with acquired generalised HSDD that causes marked distress or interpersonal difficulty. “Acquired” means the person did not have a persistent problem with sexual desire in the past; “generalized” means the problem occurs across situations, partners, and types of sexual stimulation. The diminished libido should not be primarily attributed to another medical or psychiatric condition, problems in relationships, or the use of medication or drugs.

Women who consider Nexxana Bremelanotide should make an adequate medical assessment. A clinician may look at reproductive health, medications, mental health, relationship circumstances, hormonal changes and other factors that could be contributing to decreased libido. This is important because if you treat the wrong underlying cause then there may be little benefit even if you use the medication properly.

Bremelanotide is not FDA-approved for use in men or post-menopausal women. It is also not appropriate for patients with uncontrolled hypertension or established cardiovascular disease. Pregnant individuals should not use this product and women of child-bearing potential should consult with their healthcare provider about effective contraception and pregnancy precautions. Eligibility is determined by the full medical history, not just low sexual desire.

Nexxana Bremelanotide and Other Options

Bremelanotide is one of a number of treatments being considered for low sexual desire in women. Another prescription option, flibanserin (Addyi), works through serotonin-related pathways and is taken regularly, not on-demand. The two drugs differ in their dosing schedules, mechanisms, safety issues and approved populations of patients. One is not always better or right for everybody.

Other approaches might include reviewing medications that affect libido, treating depression or anxiety, treating vaginal discomfort, checking for hormonal changes, and considering relationship or psychological counselling. Interventions may be more suitable when low sexual desire is linked to a specific underlying issue. Their effectiveness depends on the cause, and counselling or lifestyle changes should not be presented as guarantyd substitutes for medical treatment.

Searches for Bremelanotide pills, Bremelanotide oral products and Bremelanotide for men can also lead to confusion. Vyleesi is an FDA approved formulation and is not an oral tablet, but a subcutaneous injection. Oral bremelanotide products and compounded preparations should not be assumed to have the same clinical evidence, quality controls or regulatory status. Moreover, the oxytocin bremelanotide combinations are not the approved medication and do not have the same FDA-approved indications for HSDD.

Where to Buy Nexxana Bremelanotide in the US

Bremelanotide is available in the United States as a prescription drug that can be obtained through the appropriate healthcare and pharmacy channels. It is advised to assess Nexxana’s prescription-based offering by verifying the exact product formulation, the provider’s qualifications, the dispensing pharmacy and whether the medication provided is FDA-approved Vyleesi or an alternative formulation. Just because Brand X sells a product containing an approved active ingredient, it does not mean all of Brand X’s products are FDA approved.

Patients should ONLY receive bremelanotide through legitimate prescription channels and avoid unverified online sellers advertising research peptides, injectable products or Bremelanotide oral supplements. The approved injection has a specific strength and administration schedule. Other preparations may have different strengths, may not be as pure, may not have been shown to be safe, and may not be regulated at all.

Frequently Asked Questions about Bremelanotide (Nexxana)

What is Nexxana (Bremelanotide) used for?

Nexxana Bremelanotide is related to the prescription drug bremelanotide, also known as PT-141, which is used to treat low sexual desire in qualifying women. Bremelanotide is an FDA approved medication for the treatment of acquired, generalised HSDD in premenopausal women with marked distress. It is not approved for use as a general sexual performance enhancer, or for treatment of every cause of reduced libido.

Is bremelanotide FDA approved?

“Yeah. Bremelanotide is FDA-approved in the United States as Vyleesi, a prescription subcutaneous injection for treatment of acquired generalised HSDD in premenopausal women. However, just because the FDA has approved the active ingredient in one medication, that does not mean that all products that contain bremelanotide - even products sold by other brands - have been separately approved by the FDA.

What is the recommended dose of bremelanotide?

The FDA-approved dose of Vyleesi is 1.75 mg injected under the skin of the abdomen or thigh as needed, at least 45 minutes before planned sexual activity. Do not give more than one dose in 24 hours and do not recommend more than eight doses in a month. A health professional will have to decide whether this is the right treatment.

Is there a pill of bremelanotide?

The bremelanotide treatment is FDA-approved, but it’s not an oral pill - it’s an injectable. Products advertized as Bremelanotide pills or Bremelanotide oral treatments are not to be taken as having the same effectiveness, safety evidence or regulatory approval. Preparations for oral use may have different absorption characteristics and consumers should check their regulatory status prior to consideration.

Is bremelanotide effective in men?

Bremelanotide has been studied in male sexual function, but the FDA-approved Vyleesi indication does not include men. It is only approved for use in some premenopausal women with acquired generalised HSDD. Treatment Claims For Men Claims that Bremelanotide will reliably improve libido or sexual performance in men should be treated cautiously as the medication is not FDA-approved for those purposes.

How quickly does bremelanotide work?

The approved bremelanotide injection should be given at least 45 minutes before anticipated sexual activity. Results will vary from person to person and the length of time it works has not been fully determined. It’s not a pill promising an instant response or a fixed amount of sexual desire. Patients should take them as prescribed and not alter the time of administration on their own.

What are the most common side effects of bremelanotide?

The most common side effect is nausea, experienced by about 40% of patients in clinical studies. Flushing, headache, vomiting, and injection site reactions have also been reported. The medicine may cause a temporary rise in blood pressure and fall in heart rate. Localised darkening of the skin can occur less often and may persist after stopping treatment.

Is PT-141 the same as bremelanotide?

“Yeah. PT-141 is another name for bremelanotide, a synthetic peptide that activates melanocortin receptors. The terms are frequently used synonymously when referring to this compound. However, products sold as research PT-141 or compounded peptide preparations are not necessarily equivalent to the FDA-approved Vyleesi injection in formulation, manufacturing standards or clinical evidence.

Is bremelanotide similar to oxytocin?

No. Bremelanotide and oxytocin are different molecules with different biological activities. Bremelanotide activates melanocortin receptors and oxytocin is a naturally occurring hormone involved in numerous physiological and social processes. The combination of oxytocin and bremelanotide should not be considered the same as the approved bremelanotide treatment, as the effectiveness and safety of this combination for the treatment of HSDD is not established by the same FDA approval.

Is bremelanotide for postmenopausal women?

The FDA does not approve Bremelanotide for the treatment of HSDD in post-menopausal women. Changes associated with menopause, including hormonal fluctuations, vaginal dryness, and discomfort during sexual activity, may contribute to reduced desire. Such concerns should be assessed on a case-by-case basis, and other treatments might be more appropriate depending on symptoms, medical history, and cause.

Nexxana Bremelanotide: The Bottom Line

Nexxana Bremelanotide is designed to introduce consumers to bremelanotide, a prescription treatment that has clinical evidence to improve sexual desire and decrease related distress in certain premenopausal women with HSDD. What sets it apart from some other approaches to low sexual desire is its neurological mechanism and on-demand injection schedule. But its approved use is limited, and it doesn’t necessarily lead to a better libido or sexual performance.

The most important considerations are: product identity, FDA approval, individual eligibility, dosage limitations, and potential adverse effects. Special attention should be paid to nausea, transient cardiovascular changes and possible changes in skin pigmentation. To summarise, bremelanotide is an evidence-based treatment for a specific medical condition, but Nexxana-branded products and other formulations should be evaluated separately from the FDA-approved drug.